Is Standard Biotools Inc (LAB) overvalued? · rev $174.4M
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
This page asks whether Standard Biotools Inc (LAB) looks expensive on cached numbers — not a short thesis.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
LAB currently screens at market cap $317.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LAB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LAB stock page for the full model, not this heading.
Not investment advice.